🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

NBIX NBIX

Company Profile ↓
$161.50
+26.13% 1Y
P/E34.58
52W High$185.50
52W Low$123.10
EPS (TTM)$4.67

Company Overview

NBIX (NBIX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.9%.

Steady Revenue Expansion

Revenue has grown at a 53.7% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 16.7%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $2.86B (+21.4% YoY); net profit $478.60M.
  • Trailing 12 Months Year-on-year growth — revenue +21.4%, earnings +40.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 53.7%, profit CAGR 3.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:53.69%
1 Year:21.45%

Compounded Profit Growth

5 Years:3.28%
1 Year:40.23%

Stock Price Performance

1 Year:+26.13%
6 Months:+16.20%
3 Months:+19.58%
1 Month:-9.01%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 62% of range
$123.10 $185.50
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)39.33 · Neutral
Price Performance
1M-9.01%
3M+19.58%
6M+16.20%
1Y+26.13%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 53.7% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
34.58
Industry PE
-
Forward P/E est.
24.66
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
53.69%
Profit 5Y
3.28%
Revenue (YoY)
21.45%
Earnings (YoY)
40.23%

Profitability & Returns

ROCE
15.92%
ROE
14.71%
ROA
10.33%
Profit Margin
16.73%
Op Margin
21.64%
Gross Margin
-
EPS (Latest Qtr)
$1.39
EPS (TTM)
$4.67

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$5.36B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.07%
Chg in Prom Hold
-
FII / Inst Holding
104.31%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$2.86B
EBITDA
-
Free Cash Flow
$748.70M
Operating Cash Flow
$782.70M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue -------06.33M60.77M94.52M71.09M96.91M151.76M131.49M138.40M183.50M222.10M244.10M237.10M302.40M258.50M247.90M236.60M288.90M296.00M310.60M378.20M387.90M420.40M452.70M498.80M515.30M590.20M622.10M572.60M687.50M794.90M814.50M959.00M
Operating Income -25.32M-35.84M--20.86M-41.83M-38.44M--79.93M-57.27M-6.00M--37.45M-1.85M54.32M--101.00M34.40M90.10M-58.90M76.60M-44.30M-31.50M62.80M44.50M3.10M54.70M87.80M-114.20M73.60M141.20M99.30M145.40M183.80M23.60M145.60M239.00M193.40M151.50M
Net Income -23.99M-34.44M-29.32M-19.26M-40.28M-36.89M-44.66M-78.33M-59.98M-11.12M6.89M-41.82M-5.91M50.76M18.08M-102.10M51.30M53.80M34.00M37.40M79.60M-57.60M347.90M32.10M42.30M22.50M13.90M-16.90M68.50M-76.60M95.50M83.10M43.40M65.00M129.80M7.90M107.50M209.50M197.90M144.40M
Diluted EPS --------0.90-0.68-0.130.07-0.47-0.070.520.19-1.120.540.560.350.390.81-0.623.580.330.430.230.14-0.180.69-0.790.950.820.420.631.240.081.062.041.911.39
R&D Expense 18.72M24.39M-23.90M26.86M20.94M-51.88M21.87M22.46M-48.95M36.99M35.48M-37.65M61.69M--58.30M---73.20M----------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 2.95M33.50M77.41M53.14M2.92M019.77M15.00M161.63M451.20M788.10M1.05B1.13B1.49B1.89B2.36B2.86B
Operating Income -53.67M-13.72M33.92M1.45M-49.68M-64.41M-94.20M-147.37M-131.36M36.80M72.30M163.00M102.50M249.00M250.90M570.50M619.10M
Net Income -51.04M-7.97M37.57M5.03M-46.09M-60.54M-88.93M-141.09M-142.54M21.10M37.00M407.30M89.60M154.50M249.70M341.30M478.60M
Diluted EPS -1.30-0.150.670.08-0.69-0.81-1.05-1.63-1.620.220.394.160.921.562.473.294.67
R&D Expense 33.72M31.15M30.95M37.16M39.25M46.42M81.49M94.29M121.83M160.52M-------

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --144.42M138.37M195.98M154.68M243.03M474.79M365.09M817.59M993.15M1.31B1.73B2.07B2.37B3.25B3.72B4.63B
Total Equity 36.77M3.95M19.34M60.08M154.37M120.41M208.70M424.45M314.88M372.20M480.80M636.90M1.13B1.37B1.71B2.23B2.59B3.25B
Cash & Equivalents 68.47M37.33M54.05M50.11M63.75M44.79M31.01M74.19M83.27M254.71M141.71M112.30M187.10M340.80M262.90M251.10M233.00M713.00M
Total Liabilities --125.08M78.29M41.61M34.27M34.33M50.33M50.21M445.45M512.39M669.10M608.50M698.50M660.90M1.02B1.13B1.38B
Current Liabilities --52.78M47.11M15.65M11.70M15.66M25.71M30.41M54.43M88.23M565.30M186.50M245.80M537.70M654.80M507.70M743.40M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -53.09M49.94M-698.00K-35.29M-29.61M---106.18M-94.33M101.40M147.00M228.50M256.50M339.40M389.90M595.40M782.70M
Investing Cash Flow 12.06M-54.70M-3.53M-34.76M5.34M--112.95M-251.25M-242.90M-211.10M4.10M-130.20M-177.10M-467.10M-126.80M-264.40M
Financing Cash Flow 9.90M21.48M286.00K83.70M5.30M--2.39M516.65M29.50M32.40M-157.80M27.40M-234.30M65.30M-486.70M-38.30M
Capital Expenditure -35.00K-315.00K-750.00K-971.00K-545.00K-1.61M-1.93M-4.11M-6.94M-24.80M-14.70M-10.90M-23.40M-16.50M-28.30M-38.20M-34.00M
Free Cash Flow -53.13M49.63M-1.45M-36.27M-30.15M---110.29M-101.27M76.60M132.30M217.60M233.10M322.90M361.60M557.20M748.70M
Share Buybacks -------------00300.00M167.70M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % -1,817.5%-41.0%43.8%2.7%-1,701.9%--476.5%-982.5%-81.3%8.2%9.2%15.6%9.0%16.7%13.3%24.2%21.6%
Net Margin % -1,728.3%-23.8%48.5%9.5%-1,579.0%--449.8%-940.6%-88.2%4.7%4.7%38.9%7.9%10.4%13.2%14.5%16.7%
ROE % -1,290.8%-41.2%62.5%3.3%-38.3%-29.0%-21.0%-44.8%-38.3%4.4%5.8%36.2%6.5%9.0%11.2%13.2%14.7%
ROCE % --15.0%37.2%0.8%-34.7%-28.3%-21.0%-44.0%-17.2%4.1%9.8%10.5%5.6%13.6%9.7%17.8%15.9%

Shareholding Pattern

Insiders
1.07%
Institutions
104.31%
Public Float
105.45%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NBIX

Google News Sat, 01 Aug 2026

Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNUnNiaGNZLS0xUE93c2lvUlAzZk9ma0RoMTkzRmVzckdBeEFkaEkxSnFfdDc4WXgwTi1xZ1BDMGVjN0hVMlFuVllvcEVUY0J6UDdVZzd1a3BuNWJiTEhBR3pLbGJ6bmltd1RxNk0yTmlNcXpqWHZManhWUHRpSmJBZXZnaU40RjBoWU55eV…

Google News hu, 23 Jul 2026

Neurocrine Biosciences (NBIX) Stock Trades Fair On Earnings But Mixed On Value - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNNW16OEZCcDdTSnBOalRoUXNLd0tSS3RGbUpteDAtandFVFdsR2lTdUR2NUNZdTFBdXp2Y3JOa3FUbVlMRm1ZckFrVXVDMHdNSFJaVll0aXdCN1RLRV9fcmRtWEVtRWd3cXRSbDlFWEp6VnVxRk11bU5tV0tud0hIbHpiM3JWLU94VnRucV…

Google News Fri, 31 Jul 2026

$NBIX stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPQi1VVnE1YXp1Zk5JZGwxVnpqZ1U5RWVtYnZjVlY0dXBWZHlWeWtOZWpHMkRfajhURWpkUWlHQkJyOGZNWFBZTnZaNUlCZlQyOU9iRzItLU9sQzEzdVY2RWxMb3E0VEJpdThXaVpzdHU2Z0VZMTFvX0M5QWx6a0hGNlE5X3ZwWVBSODg4Z3…

Google News hu, 30 Jul 2026

Neurocrine Completes $2.9B Soleno Deal, Adds PWS Therapy - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNaTRUeXRWei03MnpqVDVVczhFdlZxOFpDMDRidmF6Nm5HN01sRklnME1nd2toY2xyazg3ZUtYTXROSjM4Qmx1dkM3a2xfbllaZFhRZmd1MVV3MXVsdjd6QnBKYTluc0twM091a3R4OUEtN0Mta0dKSGFRT3NoQ3B3TnNhTXZuUHFPRXktc3…

Google News Fri, 31 Jul 2026

Neurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S - GuruFocus

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPbFptQldpRmIzUWlYNU1VU2xuamtQcEJGT1FiOWpFTXNsNmtjay00MlY0OTYzQkNIdHVwRDNFUnhpQ2N4LWZzOFg2VzFjdjlMV09nMUI0OFVVRENvc0F1bVpGQmtBRGgzUDlhZnVDREdxc2J3Yy1veXNSUG5TTTRKRFJvQ3NYYzREX1ZrMV…

Google News Mon, 27 Jul 2026

Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setup - ChartMill

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQSHl4WjlVVVJBaDU4ZzE2eHFCdm94cFAxWEh3ejA0ejZaNDRhTTZnZUg4YjdCR0Zjb2RCN3R2QXhFcDlRSHBDY2pSb29PMGVQTTlJU3BNRmZ0TkRwaFhVUlhUM3kzYTdxYUcyRVpWYnJlbGN5NHVVTkh3Z3BhaVMtWmM0VGZ5NkpFYk1KRm…

NBIX — Frequently Asked Questions

What is the current share price of NBIX?

As of 2026-08-05 17:25 PDT, NBIX trades at $161.50 on NASDAQ/NYSE. Its 52-week range is $123.10 to $185.50.

What is the P/E ratio of NBIX?

NBIX trades at a trailing price-to-earnings (P/E) ratio of 34.58.

What is the return on equity (ROE) of NBIX?

NBIX has a return on equity (ROE) of 14.71%. Its return on capital employed (ROCE) is 15.92%.

Is NBIX a good stock to buy?

This page provides a data-driven analysis of NBIX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space